Journal article

Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium

AR Kreimer, A Ferreiro-Iglesias, M Nygard, N Bender, L Schroeder, A Hildesheim, HA Robbins, M Pawlita, H Langseth, NF Schlecht, LF Tinker, I Agalliu, SW Smoller, E Ness-Jensen, K Hveem, G D'Souza, K Visvanathan, B May, G Ursin, E Weiderpass Show all



BACKGROUND: Human papillomavirus type 16 (HPV16)-E6 antibodies are detectable in peripheral blood before diagnosis in the majority of HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), but the timing of seroconversion is unknown. PATIENTS AND METHODS: We formed the HPV Cancer Cohort Consortium which comprises nine population cohorts from Europe, North America and Australia. In total, 743 incident OPSCC cases and 5814 controls provided at least one pre-diagnostic blood sample, including 111 cases with multiple samples. Median time between first blood collection and OPSCC diagnosis was 11.4 years (IQR = 6-11 years, range = 0-40 years). Antibodies against HPV16-E6 were measured by mult..

View full abstract


Awarded by US National Cancer Institute

Awarded by Australian NHMRC

Awarded by National Cancer Institute P30 grants

Awarded by National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services

Funding Acknowledgements

HPVC3 was funded by a grant from the US National Cancer Institute (grant: 5U01CA195603-02), with additional support from the intramural program of the Division of Cancer Epidemiology and Genetics, US NCI. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants (209057 and 396414) and by infrastructure provided by Cancer Council Victoria. Cases were ascertained through the Victorian Cancer Registry (VCR) and the Australian Cancer Database (Australian Institute of Health and Welfare). Involvement of the Women's Health Initiative (WHI) collaborators was supported in part by National Cancer Institute P30 grants to the Roswell Park Comprehensive Cancer Institute (CA016056), and Einstein Cancer Research Center (CA013330). The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts (HHSN26820 1600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C).